Anzeige
Meldung des Tages: Gold bei 5.250 USD – Dieser 37-Mio.-€-Goldentwickler sitzt auf einem möglichen $2-Milliarden-Projekt!!

Savara

Aktie
WKN:  A2DQ2B ISIN:  US8051111016 US-Symbol:  SVRA Branche:  Biotechnologie Land:  USA
5,30 $
-0,235 $
-4,25%
4,6017 € 20:16:19 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,11 Mrd. €
Streubesitz
11,72%
KGV
-6,40
Index-Zuordnung
-

Unternehmensmeldungen

06.03.26 - Businesswire
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (the “Company”) (Nasdaq: SVRA ), a clinical-​stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 ...
04.03.26 - Businesswire
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management ...
20.02.26 - Businesswire
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-​stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for ...
13.02.26 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
04.02.26 - Businesswire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management ...
27.01.26 - Businesswire
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and ...
16.01.26 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new ...
08.01.26 - Businesswire
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical ...
22.12.25 - Businesswire
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the ...
17.12.25 - Businesswire
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management ...

Newssuche

Videos

newspaper
10.03.26 -6,06%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »